Loading quotes...
Forecast
The analysts' average price target is €435.05 (+7.95%). The median is €448.10 (+11.19%).
| Buy |
Â
40 |
| Hold |
Â
12 |
| Sell |
Â
5 |
News Go to news feed
Intuitive Surgical back at yearly high after Q3 numbers – stock rebounds after sell-off
Intuitive Surgical beat revenue and earnings expectations in the third quarter, pushing the share price back up after a temporary pullback of around ten percent. The stock outperformed the market and briefly reached its highest level since May, sustainably breaking above the 200-day moving average. Analysts view the pullback as a buying opportunity despite concerns about comparison effects and growth worries in the U.S. » More on deraktionaer.de
Intuitive Surgical beats expectations, stock falls after $450m settlement
Intuitive Surgical reported third-quarter revenue up 22% to $3.05 billion and adjusted earnings per share of $3.00, both well above analysts’ estimates. Procedures using surgical robots rose 15% and the installed base of Da‑Vinci systems topped 12,000 units for the first time. Despite the strong results, the stock sank by just over ten percent at one point after the company said it will pay a $450 million settlement. Intuitive holds $6.8 billion in cash and announced share buybacks of about $2.94 billion. » More on deraktionaer.de
Intuitive Surgical ahead of quarterly results: US procedures and guidance in focus
Intuitive Surgical will report third-quarter results on Tuesday after the US market close. Analysts expect revenue of $2.91 billion and adjusted earnings per share of $2.65. Key for the stock is whether management classifies the slowed growth in Da Vinci procedures in the US as temporary and raises the full-year guidance; the shares are currently about 30% below their 52-week high and just under the 200-day moving average. Competitive pressure from Stryker and CMR Surgical is cited as an additional risk factor. » More on deraktionaer.de
Financials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 2.69B | 26.09% |
| Gross profit | 1.84B | 29.90% |
| Net profit | 461.55M | 23.11% |
| EBITDA | 590.1M | 31.79% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €143.2B |
Number of shares | 353.28M |
52-week high/low | €541.20 - €294.47 |
| Dividends | No |
Beta | 1.46 |
P/E ratio | 54.04 |
PEG ratio | 6.11 |
P/B ratio | 9.87 |
P/S ratio | 13.80 |
Company profile
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing unified and connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
| Name | Intuitive Surgical |
| CEO | David J. Rosa |
| Headquarters | Sunnyvale,
ca USA |
| Website | |
| Sector | Health Care |
| Industry | Health Care Technology |
| IPO | 08/10/2023 |
| Employees | 17,021 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | ISRG |
London Stock Exchange | 0R29.L |
XETRA | IUI1.DE |
Frankfurt | IUI1.F |
DĂĽsseldorf | IUI1.DU |
Hamburg | IUI1.HM |
Milan | 1ISRG.MI |
London | 0R29.L |
SIX | ISRG.SW |
MĂĽnchen | IUI1.MU |
Wien | ISRG.VI |